NCT07627074Completed
Weight Loss in Adults Using Semaglutide (Real-world Study)
Real-world Weight Outcomes in Adults Treated With Semaglutide s.c. 1.0 mg or 1.7 mg for Weight Management: a Non-interventional Cohort Study
Source: ClinicalTrials.gov · Last updated 4 Sept 2026
Brief summary (registry, in English)
The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 237211 (actual)
- First submitted
- 30 May 2026
- Start date
- 12 May 2026
- Primary completion date
- 15 Jun 2026
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Obesity
- NCT number
- NCT07627074
What you commit to
- Study type: Observational
- Participants enrolled: 237211
- From 12 May 2026 to the primary completion date, 15 Jun 2026
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) based medication or other obesity management medication (OMMs).
- Bariatric surgery at baseline.
Other illness
- Diabetes at baseline.
Other
- Pregnancy at baseline.
Who the study is looking for
- Initiation of semaglutide for weight management during the study period.
- Age more than or equal to (≥) 18 at treatment initiation
- Baseline body mass index (BMI) ≥27 and less than (\<) 30 kilogram per meter square (kg/m\^2) with at least one weight-related comorbidity, or BMI ≥30 kg/m\^2.
- Other inclusion criteria as defined in the protocol are applicable.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novo Nordisk Investigational Site Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
| Novo Nordisk Investigational Site Coordinator of this site? Confirm its status | Seattle | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.